Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 20.07
(0.25%)
CNY 20.07
(0.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 301.24 Million CNY | -6.68% |
| 2022 | 287.66 Million CNY | 13.59% |
| 2021 | 253.23 Million CNY | 25.28% |
| 2020 | 202.14 Million CNY | 24.44% |
| 2019 | 162.45 Million CNY | 12.87% |
| 2018 | 143.92 Million CNY | 35.33% |
| 2017 | 106.35 Million CNY | 77.41% |
| 2016 | 59.94 Million CNY | 210.45% |
| 2015 | 19.31 Million CNY | 14.23% |
| 2014 | 16.9 Million CNY | 1.59% |
| 2013 | 16.63 Million CNY | 348.43% |
| 2012 | 3.71 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 93.03 Million CNY | 27.82% |
| 2024 Q1 | 63.01 Million CNY | -36.53% |
| 2024 Q2 | 72.78 Million CNY | 15.5% |
| 2023 Q2 | 79.46 Million CNY | 21.34% |
| 2023 Q4 | 99.29 Million CNY | 92.26% |
| 2023 FY | 268.45 Million CNY | -6.68% |
| 2023 Q1 | 65.49 Million CNY | 108.38% |
| 2023 Q3 | 51.64 Million CNY | -35.01% |
| 2022 Q3 | 150.31 Million CNY | 220.78% |
| 2022 Q2 | 46.85 Million CNY | -20.65% |
| 2022 FY | 287.66 Million CNY | 13.59% |
| 2022 Q1 | 59.05 Million CNY | 5.03% |
| 2022 Q4 | 31.42 Million CNY | -79.09% |
| 2021 Q1 | 49.65 Million CNY | -13.06% |
| 2021 FY | 253.23 Million CNY | 25.28% |
| 2021 Q4 | 56.22 Million CNY | -21.82% |
| 2021 Q2 | 75.43 Million CNY | 51.91% |
| 2021 Q3 | 71.91 Million CNY | -4.66% |
| 2020 Q2 | 63.28 Million CNY | 110.54% |
| 2020 FY | 202.14 Million CNY | 24.44% |
| 2020 Q1 | 30.05 Million CNY | -10.92% |
| 2020 Q4 | 57.11 Million CNY | 10.51% |
| 2020 Q3 | 51.68 Million CNY | -18.32% |
| 2019 Q4 | 33.74 Million CNY | -16.1% |
| 2019 FY | 162.45 Million CNY | 12.87% |
| 2019 Q3 | 40.21 Million CNY | -20.63% |
| 2019 Q2 | 50.66 Million CNY | 33.96% |
| 2019 Q1 | 37.82 Million CNY | 12.95% |
| 2018 Q1 | 28.61 Million CNY | -6.58% |
| 2018 Q4 | 33.48 Million CNY | 9.57% |
| 2018 FY | 143.92 Million CNY | 35.33% |
| 2018 Q3 | 30.56 Million CNY | -40.37% |
| 2018 Q2 | 51.25 Million CNY | 79.14% |
| 2017 FY | 106.35 Million CNY | 77.41% |
| 2017 Q1 | 18.38 Million CNY | 54.49% |
| 2017 Q3 | 26.66 Million CNY | -13.09% |
| 2017 Q2 | 30.67 Million CNY | 66.89% |
| 2017 Q4 | 30.62 Million CNY | 14.87% |
| 2016 Q3 | 19.83 Million CNY | 46.46% |
| 2016 Q1 | 13.54 Million CNY | 0.0% |
| 2016 FY | 59.94 Million CNY | 210.45% |
| 2016 Q4 | 11.89 Million CNY | -40.0% |
| 2016 Q2 | 13.54 Million CNY | -0.0% |
| 2015 Q1 | 6.68 Million CNY | 0.0% |
| 2015 FY | 19.31 Million CNY | 14.23% |
| 2015 Q2 | 6.68 Million CNY | 0.0% |
| 2014 FY | 16.9 Million CNY | 1.59% |
| 2013 FY | 16.63 Million CNY | 348.43% |
| 2012 FY | 3.71 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 69.819% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 87.887% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | -1.473% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 49.275% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | -7.929% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | 9.029% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | 45.142% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -607.157% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | -99.966% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 321.792% |